Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Mr Arvind Lal as Executive Director of the company w.e.f. April 01, 2027.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal Path Labs reported FY2026 standalone revenue of INR 27,629 million (up 12% YoY) and net profit of INR 5,098 million. The board approved final dividend of INR 4 per share for FY2026, bringing total annual dividend to INR 20.5 per share. Key leadership continuity was confirmed with re-appointment of promoter Dr. Arvind Lal as Executive Chairman for 5 years from April 2027, and Rajit Mehta as Independent Director for 5 years from July 2026. The company announced acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited and incorporation of a wholly owned subsidiary in Dubai. Two senior executives (Dr. Reena Nakra and Dr. Saloni Khera) were designated as Senior Management Personnel. The 32nd AGM is scheduled for July 25, 2026.
Positive signals for shareholders: strong financial growth, generous dividend payout, and leadership continuity with promoter at the helm. The acquisition and international expansion into Dubai indicate growth ambitions. The ESOP allotment (82,750 shares) may help retain key talent.